Menu

Search for:

Skip navigation Menu

Regulatory
Legal
News
About RFEM
Search

Search for:

Logout

You are here:

Home
Logout

Logout

Sign Up for Updates

Don’t worry. We don’t spam.

Leave this field empty if you're human:

Practice Contacts

E. Anthony Figg
Joseph A. Hynds
Seth Cockrum

Featured Posts

U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

August 1, 2019
House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

July 25, 2019
What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO

Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

About Us
Results
Careers
Practices
Publications
News & Events
Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

Disclaimer
Privacy Policy

Back to Top